SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/282483"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/282483" > High therapeutic ef...

High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia

Warsame, Marian (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
Hassan, A. M. (författare)
Hassan, A. H. (författare)
visa fler...
Jibril, A. M. (författare)
Khim, N. (författare)
Arale, A. M. (författare)
Gomey, A. H. (författare)
Nur, Z. S. (författare)
Osman, S. M. (författare)
Mohamed, M. S. (författare)
Abdulrahman, A. (författare)
Yusuf, F. E. (författare)
Amran, J. G. H. (författare)
Witkowski, B. (författare)
Ringwald, P. (författare)
visa färre...
 (creator_code:org_t)
2019-07-11
2019
Engelska.
Ingår i: Malaria Journal. - : Springer Science and Business Media LLC. - 1475-2875. ; 18
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DHA/PPQ) are the recommended first- and second-line treatments, respectively, for uncomplicated falciparum malaria in Somalia. The studies reported here were conducted to assess the efficacy of these artemisinin-based combinations and the mutations in Plasmodium falciparum K13-propeller (Pfk13) domain and amplification in Pfplasmepsin 2 (Pfpm2) gene in Somalia. Methods: One-arm prospective studies were conducted to assess the clinical and parasitological responses to DHA/PPQ and AL at two sites in 2016 and 2017, respectively, using the standard WHO protocol. The patterns of molecular markers associated with artemisinin and PPQ resistance were investigated for the first time in Somalia. Results: A total of 339 patients were enrolled with 139 for AL and 200 for DHA/PPQ. With AL, no parasite recurrence was observed among patients treated at either site, corresponding to 100% clinical and parasitological responses. For DHA-PPQ, an adequate clinical and parasitological response rate > 97% was observed. All study patients on both treatments at both sites were parasite-free on day 3. Of the 138 samples with interpretable results for the polymorphism in Pfk13, only one (0.7%), from Bosaso, contained a non-synonymous mutation (R622I), which is not one of the known markers of artemisinin resistance. No Pfpm2 amplification was observed among the 135 samples with interpretable results. Conclusions: AL and DHA/PPQ were highly effective in the treatment of uncomplicated falciparum malaria, and there was no evidence of resistance to artemisinin or PPQ. These two combinations are thus relevant in the chemotherapeutic strategy for malaria control in Somalia.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Nyckelord

Artemether-lumefantrine
Dihydroartemisinin-piperaquine
Plasmodium falciparum
Artemisinin resistance
Piperaquine resistance
Somalia
resistant plasmodium-falciparum
sulfadoxine-pyrimethamine
artesunate-amodiaquine
artemisinin resistance
sentinel sites
cambodia
combination
failure
spread
tolerability
Infectious Diseases
Parasitology
Tropical Medicine

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy